Thus, higher soluble CD19 levels (sCD19) were associated with a greater frequency of neurological symptoms in DLBCL and BL and with parenchymal CNS lymphoma in DLBCL, sCD19 emerging as a powerful predictor of event-free and overall survival in DLBCL and BL, particularly when combined with FCM detection of CNS disease.
INTRODUCTION

Primary or secondary central nervous system (CNS) involvement by B-cell non-
Hodgkin's lymphoma (NHL) is a relatively rare condition associated with a very poor prognosis 1,2 . Currently, it is well-established that flow cytometry (FCM) has a greater sensitivity than conventional cytology (CC) for the detection of cerebrospinal fluid (CSF) infiltration in Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) patients at risk of CNS disease [3] [4] [5] [6] [7] [8] . However, still a significant proportion of FCM -/CC -cases (≈10%) presents with highly suspicious neurological symptoms and/or parenchymal CNS disease 3, 5, 7, 8 . Moreover, recent data indicates that some FCMnegative cases may develop overt CNS disease early after diagnosis, particularly when CNS-directed prophylaxis had not been administrated 8 .
Altogether, these findings support the notion that parenchymal involvement of CNS by aggressive B-NHL could go undetected by both CC and FCM because, in the absence of leptomeningeal disease, lymphoma cells would not reach the CSF in detectable numbers 9 . Although recirculation of tumor cells through CSF might still exist in such cases 10 , it could be hypothesized that if an increased turnover of lymphoma cells occurs inside the brain, tumor cell products (e.g. proteins, RNA, DNA and microvesicles) would be released at abnormally high rates into the extracellular medium. Under such circumstances, the lymphoma cell components could potentially reach the CSF. Actually, higher levels of specific miRNAs (e.g. miR-19b, miR-21 and miR-92a) and proteins (e.g. CD27) have been reported in CSF from CNS lymphoma vs.
CNS lymphoma-free patients [11] [12] [13] [14] . However, in these studies, no B-cell specific markers expressed by every lymphoma case, have been investigated. Statistical methods. Receiver operating curve (ROC) analysis was performed in a subgroup of 40 CSF samples to establish the most accurate cut-off values for each CSF marker, including sCD19 (≥1.18ng/mL); sCD19 was further evaluated in another 73 CSF samples using the same (most informative) cut-off (n=113). Event-free survival (EFS) and overall survival (OS) were determined by the Kaplan-Meier method and compared by the log-rank test. Multivariate Cox proportional hazard models (stepwise regression) were developed to explore the independent effect of different parameters on EFS and OS.
RESULTS AND DISCUSSION
First, we analyzed the CSF levels of a panel of 13 B-cell associated markers in 40 B-NHL patients at risk of CNS disease, classified according to the presence vs. absence of CNS disease by FCM and/or presence of highly suspicious neurological symptoms. From all markers investigated in these 40 cases, only sCD19 (≥1.18ng/mL) and to a lesser extent also β 2 -microglobulin (≥2.56ng/mL), showed a significant association (p<.05) with CNS disease, with an accuracy of 88% and 78%, respectively (vs. <70% for all the other markers) (Supplementary Table 1 and supplementary Figure   1 ). Of note, CD19 was the only protein investigated which is both a pan-B cell marker and a B-cell specific protein 16 . All other markers display either a pattern of expression restricted to specific B-cell maturation stages and to some subtypes of B-NHLincluding BL and DLBCL-where they are expressed at variable percentages (e.g. CD21
For [17] [18] [19] , and/or they are also expressed by cells other than B-cells from brain tissues (e.g. neurons, astrocytes, glial and glioma cells) [20] [21] [22] . Overall, this could contribute to explain why sCD19 emerged as the marker with the highest degree of association with CNS lymphoma. However, the biological significance of sCD19 remains to be fully elucidated.
Further analysis of sCD19 in the whole cohort of 113 patients ( . Despite a similar frequency of occult leptomeningeal disease was found in these and our series, only two of our patients had CNS recurrence, which is probably due to the administration of active therapy to most (71%) of our FCM + cases. Consequently, it was not possible to establish here, the impact of sCD19 on CNS relapse-free survival. However, previous
For personal use only. on January 29, 2018. by guest www.bloodjournal.org From studies have also recurrently shown that occult leptomeningeal disease by FCM has a clear impact on OS, of both DLBCL and BL 6, 23 . In this regard, we also found an association between higher sCD19 CSF levels and a shorter EFS and OS among DLBCL (p=.02 and p=.002, respectively; Figure 1A Tables 2 and 3 ). 
Footnotes:
The online version of the article contains a data supplement. 
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